The impact of advanced glycation end products and their receptors on the development and prognosis of colorectal cancer.

PURPOSE: The purpose of this study was to analyze whether advanced glycation end products (AGEs) and their receptors had an impact on the development and prognosis of colorectal cancer (CRC).

METHODS

This study examined the databases of PubMed, Embase, Cochrane Library databases and CNKI up to 7 February 2024 for cohort studies assessing the association between AGEs and their receptors, including receptor for advanced glycation end products (RAGE) and soluble receptor for advanced glycation end products (sRAGE) on the development and prognosis of CRC.

RESULTS

The meta-analysis included eight studies with a total of 8,278 participants. It demonstrated that sRAGE expression was significantly lower in CRC patients compared to controls. In contrast, no significant differences were found in the expression levels of RAGE or AGEs between CRC patients and controls. Overall survival was not significantly associated with RAGE expression levels. Subgroup analysis indicated that the inverse association between sRAGE and CRC was significant in the general population but not observed among diabetic patients.

CONCLUSION

Low sRAGE expression was associated with an increased risk of CRC development, whereas RAGE and AGEs were not associated with the development and prognosis of CRC.